CoChat

Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries

Open access
Seidman, Gabriel, Atun, Rifat · 2017 · BMJ Global Health

The DOI matches its Crossref record; 47 of the 52 references it cites were found in a registry or an index; 6 of the 17 sources its claims cite were checked for support.

Abstract

Systematic review of 38 studies on whether procurement and supply chain changes achieve cost savings and improve availability of health products in LMICs.

Overview

CoChat Summary

TL;DR

This systematic review found that changes to supply chains and procurement processes in low- and middle-income countries often reduce costs and sometimes improve availability of pharmaceuticals, vaccines, and other health products. Centralised procurement/tendering showed cost savings across many contexts, while supply chain management programmes often reduced stock-outs and increased availability.

Key findings

  • The review screened 1,264 articles and included 38 studies: 25 on cost implications and 15 on availability, with 2 studies contributing to both groups.
  • Of the 25 references analysing cost implications, 23 found a reduction in costs to the health system; 12 of these focused on centralised procurement or tendering.
  • Centralised procurement produced reported savings such as 5.2–17% cost savings on drugs in Jordan, US$52.1 million–US$121.8 million in savings in Mexico over the first 4 years, and a 79% reduction in annual ARV cost per person in Brazil over 6 years (1997 to 2003).
  • Of the 15 references analysing availability, 13 found improvements; supply chain management programmes were linked to reduced stock-outs and increased availability, including increases from 40% to 70% before implementation to >90% after implementation in Delhi, India.

Methods

  • Systematic review conducted using PRISMA guidelines.
  • Searched PubMed, Embase, CINAHL, and the Health Economic Evaluation Database; included original peer-reviewed studies in English reporting actual interventions in LMICs.
  • Included studies had to evaluate an intervention changing procurement or supply chains and report cost changes or product availability; the review used comparative outcome measures and excluded baseline costing studies and non-intervention reports.

Limitations

  • The paper states that studies used many different metrics, making it hard to compare or synthesise findings across studies.
  • It states that many studies did not use experimental designs, and there is likely publication bias toward positive results; very few studies reported negative outcomes.
  • Evident from the text: the review’s conclusions are constrained by context-specific interventions, so effects may not generalise well across settings; the paper explicitly says one cannot predict the impact of a specific programme in another context.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjgh-2016-000243

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study selection for inclusion in systematic review.
Figure 1 Study selection for inclusion in systematic review.CC BY-NC · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 8 Not checked · 16 Own results and interpretations

21 more claims

Create a free account to see all 31 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 5
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 47 references

Research works printed but not linked: 3

  1. 10.1002/(SICI)1099-1751(199706)12:1+<S29::AID-HPM465>3.3.CO;2-L · doi:10.1002/(sici)1099-1751(199706)12:1+<s29::aid-hpm465>3.3.co;2-l
  2. Embrey M . Chapter 13: Revolving drug funds and user fees. In: Management Sciences for Health, eds. MDS-3: managing access to medicines and health technologies. Arlington (VA): Management Sciences for Health, 2012.
  3. Barraclough A , Clark M . Chapter 18: managing procurement. In: Management Sciences for Health, eds. MSD-3 managing access to medicines and health technologies. Arlington (VA): Management Sciences for Health, 2012.

Cited by

See all 133

Metadata

Authors
Seidman, G., & Atun, R.
Affiliations
Harvard University (US)
Corresponding author
Seidman, Gabriel
Venue
BMJ Global Health
Publisher
BMJ
Published
2017-04
Volume
2
Issue
2
Pages
e000243
ISSN
2059-7908 (ISSN-L)
OpenAlex
W2607163485
Cited by
133
References
52
Citations by year
2026: 14 · 2025: 21 · 2024: 26 · 2023: 15 · 2022: 15 · 2021: 19 · 2020: 9 · 2019: 8 · 2018: 3 · 2017: 2
FWCI
2.11
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Global Health (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • Bill and Melinda Gates Foundation
  • Rockefeller Foundation
  • Harvard T.H. Chan School of Public Health
  • Bloomberg Philanthropies
  • GE Foundation
  • Harvard Kennedy School
  • Harvard Graduate School of Education
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
  • Social Sciences › Decision Sciences › Management Science and Operations Research › Supply Chain and Inventory Management
Keywords
pharmaceutical supply chain, tendering, drug stock-outs, drug availability, cost reduction, health system efficiency, vaccines, low- and middle-income countries, health system performance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. https://app.cochat.ai/papers/10.1136/bmjgh-2016-000243
The paper
Seidman, G., & Atun, R. (2017). Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Global Health. https://doi.org/10.1136/bmjgh-2016-000243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.